|
1.
|
|
20 p, 1.9 MB |
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types
/
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Gómez, Maica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García Vidal, Edurne (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Romeo, Margarita (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Morán, Teresa (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Layos, Laura (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Pérez-Roca, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Fernández, Pedro Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ample evidence exists connecting dNTP pool dysregulation to cancer and genomic instability. SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. [...]
2022 -  10.20944/preprints202201.0141.v1
Cancers, Vol. 14 Núm. 3 (january 2022)
|
|
|
2.
|
|
13 p, 2.2 MB |
Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
/
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesia, Carles (Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l'Hospitalet de Llobregat, Barcelona, Spain) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ;
Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ;
Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). [...]
2018 - 10.18632/oncotarget.25478
Oncotarget, Vol. 9 (june 2018) , p. 27074-27086
|
|
|
3.
|
|
12 p, 700.5 KB |
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain : OSIREX-Spanish Lung Cancer Group
/
Provencio, Mariano (Universidad Autónoma de Madrid) ;
Terrasa, Josefa (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Garrido, Pilar (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Campelo, Rosario García (Instituto de Investigación Biomédica A Coruña INIBIC) ;
Aparisi, Francisco (Hospital General Universitario de Valencia) ;
Diz Taín, P (Complejo Asistencial Universitario de León. Medical Oncology Department León) ;
Aguiar, David (Hospital Universitario de Gran Canaria Dr. Negrín) ;
García-Giron, Carlos (Hospital Universitario de Burgos) ;
Hidalgo, Julia (Hospital Lluís Alcanyis. Medical Oncology Department) ;
Aguado, Carlos (Hospital Clínico San Carlos (Madrid)) ;
González, Jorge García (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Esteban, Emilio (Hospital Universitario Central de Asturias) ;
Gómez-Aldavarí, Lorenzo (Complejo Hospitalario Universitario de Albacete) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe de València) ;
Chara, Luís Enrique (Hospital Universitario de Guadalajara) ;
Marti, Juan L. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Castro, Rafael López (Hospital Clínico Universitario de Valladolid) ;
Ortega, Ana Laura (Complejo Hospitalario de Jaén) ;
Moreno, Elia Martínez (Hospital Virgen de la Salud (Toledo)) ;
Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Sánchez Peña, Ana M. (Hospital Universitario de Getafe (Madrid)) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
Gastaldo, Amparo Sánchez (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Núñez, Natalia Fernández (Hospital Universitario Lucus Augusti (Lugo)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Cobo, Manuel (Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Unidad de Gestión Clínica Intercentros de Oncología Médica) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Navarro, Fátima (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid)) ;
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
AURA study reported 61% objective response rate and progression-free survival of 9. 6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain. [...]
2021 - 10.1186/s12885-021-07922-5
BMC Cancer, Vol. 21 (march 2021)
|
|
|
4.
|
|
10 p, 2.7 MB |
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
/
Yamamoto, Nobuyuki (Wakayama Medical University. Third Department of Internal Medicine) ;
Hayashi, Hidetoshi (Kindai University Faculty of Medicine. Department of Medical Oncology) ;
Planchard, David (Institut Gustave Roussy (Villejuif, França)) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gregorc, Vanesa (IRCCS Ospedale San Raffaele. Department of Oncology, Division of Experimental Medicine) ;
Dowell, Jonathan (University of Texas Southwestern Medical Center. Department of Internal Medicine) ;
Sakai, Hiroshi (Saitama Cancer Center. Department of Thoracic Oncology) ;
Yoh, Kiyotaka (National Cancer Center Hospital East. Department of Thoracic Oncology) ;
Nishio, Makoto (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Department of Thoracic Medical Oncology) ;
Cortot, Alexis B. (Centre Hospitalier Universitaire de Lille. Thoracic Oncology Department) ;
Benhadji, Karim A. (Taiho Oncology, Inc. Department of Clinical Development) ;
Soni, Nital (Taiho Oncology, Inc. Department of Clinical Development) ;
Huang, Jinhong (Taiho Pharmaceutical Co., Ltd. Department of Pharmacovigilance) ;
Makris, Lukas (Stathmi, Inc, 125 Brownsburg Rd, New Hope, PA 18938 USA) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00930-5) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00930-5
Investigational New Drugs, Vol. 38 (april 2020) , p. 1588-1597
|
|
|
5.
|
|
1 p, 789.3 KB |
Correction : Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
/
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesia, Carles (Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l'Hospitalet de Llobregat, Barcelona, Spain.) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ;
Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ;
Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
2019 - 10.18632/oncotarget.26855
Oncotarget, Vol. 10 (april 2019) , p. 2576
|
|
|
6.
|
|
13 p, 2.1 MB |
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study
/
Conde, Esther (Hospital Universitario HM Sanchinarro (Madrid)) ;
Hernández, Susana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Martinez, Rebeca (Hospital Universitario HM Sanchinarro (Madrid)) ;
Angulo, Bárbara (Hospital Universitario HM Sanchinarro (Madrid)) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Jimenez, Beatriz (Hospital Universitario HM Sanchinarro (Madrid)) ;
Muriel, Alfonso (Hospital Universitario Ramón y Cajal (Madrid)) ;
Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aranda, Ignacio (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Massuti, Bartomeu (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Rojo, Federico (Centro de Investigación Biomédica en Red de Cáncer) ;
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Garcia, Felip (Quironsalud Hospital) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Mancheño, Nuria (Hospital Universitari i Politècnic La Fe de València) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe de València) ;
Sanz, Julián (Hospital Clínico San Carlos (Madrid)) ;
Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ;
Atienza-Cuevas, Lidia (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Arriola-Arellano, Esperanza (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Abdulkader, Ihab (Clinico de Santiago University Hospital) ;
Garcia-Gonzalez, Jorge (Clinico de Santiago University Hospital) ;
Camacho, Carmen (Insular Materno-Infantil University Hospital Complex) ;
Rodríguez-Abreu, Delvys (Insular Materno-Infantil University Hospital Complex) ;
Teixido, Cristina (Clinic Hospital) ;
Reguart, Noemi (Clinic Hospital) ;
Gonzalez-Piñeiro, Ana (Alvaro Cunqueiro Hospital) ;
Lazaro-Quintela, Martín (Alvaro Cunqueiro Hospital) ;
Lozano, María Dolores (Clínica Universidad de Navarra) ;
Gurpide, Alfonso (Clínica Universidad de Navarra) ;
Gómez-Román, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Lopez-Brea, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ;
Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
Company, Amparo (Clinico University Hospital) ;
Insa, Amelia (Clinico University Hospital) ;
Esteban-Rodriguez, Isabel (Hospital Universitario La Paz (Madrid)) ;
Saiz, Mónica (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Azkona, Eider (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Alvarez, Ramiro (Hospital Universitario Miguel Servet (Saragossa)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Plaza, María Luz (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Aguiar de Sousa, Diana (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Enguita, Ana Belén (Hospital Universitario 12 de Octubre (Madrid)) ;
Benito, Amparo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ;
Lopez-Rios, Fernando (Hospital Universitario HM Sanchinarro (Madrid)) ;
Universitat Autònoma de Barcelona
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. [...]
2019 - 10.1016/j.jtho.2019.07.005
Journal of Thoracic Oncology, Vol. 14 Núm. 12 (december 2019) , p. 2120-2132
|
|
|
7.
|
|
8 p, 713.1 KB |
Transbronchial and transesophageal fine-needle aspiration using a single ultrasound bronchoscope in the diagnosis of locoregional recurrence of surgically-treated lung cancer
/
Sanz-Santos, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Serra, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Andreo García, Felipe (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Torky, Mohamed (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Centeno, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernández Araujo, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Reina, Samuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruiz Manzano, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The present study sought to evaluate the usefulness of EBUS-TBNA in the diagnosis of locoregional recurrence of lung cancer in a cohort of lung cancer patients who were previously treated surgically, and describe our initial experience of EUS-B-FNA in this clinical scenario. [...]
2017 - 10.1186/s12890-017-0388-4
BMC Pulmonary Medicine, Vol. 17 (february 2017)
|
|
|
8.
|
|
8 p, 738.8 KB |
The epidermal growth factor receptor (EGRF) in lung cancer
/
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Capdevila, Laia (Hospital Sant Pau i Santa Tecla (Tarragona)) ;
Cros Costa, Sara (Hospital General de Granollers) ;
Vilà, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
de los Llanos Gil, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Remón, Jordi (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Rosell, Rafael (Fundación Molecular Oncology Research) ;
Universitat Autònoma de Barcelona
In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. [...]
2015 - 10.1186/s40247-015-0013-z
Translational Respiratory Medicine, Vol. 3 (february 2015)
|
|
|
9.
|
|
8 p, 455.0 KB |
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial
/
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Keedy, Vicki (Vanderbilt University Medical Center) ;
Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ;
Shepherd, Frances A. (University of Toronto) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Brown, Holly (Merck & Co., Inc., Whitehouse Station) ;
Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ;
Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ;
Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ;
Mauro, David (Merck & Co., Inc., Whitehouse Station) ;
Hsu, Karl (Sanofi Aventis) ;
Yan, Li (Merck & Co., Inc., Whitehouse Station) ;
Universitat Autònoma de Barcelona
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). [...]
2014 - 10.1186/2162-3619-3-26
Experimental Hematology & Oncology, Vol. 3 (november 2014)
|
|
|
10.
|
|
12 p, 942.4 KB |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
/
Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ;
Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ;
Pilotto, Sara (University of Verona (Itàlia)) ;
Drozdowskyj, Ana (Pivotal (Madrid)) ;
Codony Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ;
Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ;
Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ;
Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ;
Gervais, Radj (Centre François Baclesse (Caen, França)) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ;
Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ;
Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ;
De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ;
Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ;
Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ;
Bria, Emilio (University of Verona (Itàlia)) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
